Previous Close | 39.11 |
1-Year Change | 36.46% |
6-Months Change | 13.2% |
3-Months Change | 10.95% |
Moving Avg (50d) | 37.552 |
Moving Avg (200d) | 32.877 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.12B |
Beta (3-Years) | 0.65 |
Revenue Growth (ttm) | -7.35% |
Net Profit Margin (ttm) | 4.2% |
Return On Assets (ttm) | 1.99% |
EPS (ttm) | 0.4 |
PE Ratio (ttm) | 97.78 |
Dividend Yield | % |
Asset Description: | Supernus Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2025-02-10 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
39.892 | 41.066 | 41.848 | 43.021 | 44.977 | 46.932 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Pharmaceuticals |
Country: | United States |